CRISPR Therapeutics AG public offering of an aggregate 4,887,500 common shares

On 20 November 2019, CRISPR Therapeutics AG launched its public offering of an aggregate 4,887,500 common shares on Nasdaq raising approximately USD 315.2 million. CRISPR Therapeutics is a leading gene editing company based in Zug, Switzerland, focusing on developing transformative gene-based medicines for serious diseases based on its proprietary CRISPR/Cas9 technology.